74187-86-3

Upstream product

• 1937-19-5 1-aminoguanidine hydrochloride 
• 100-52-7 benzaldehyde 
• 2582-30-1 aminoguanidine bicarbonate 

Downstream Products

• 677737-57-4 (E)-4-phenyl-N¹-(phenylmethylene)-1H-imidazole-1,2-diamine 
• 132707-61-0 2-Phenyl-1,2-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 
• 146903-59-5 (E)-N-<(phenylmethyleneamino)amidino>acetamide 
• 147348-02-5 2C₁₀H₁₂N₄O*H₂O₄S 

Relevant academic research and scientific papers

Modified synthesis of some 1-(pyrimidin-2-yl)-3-methyl-4-arylidenepyrazol- 5(4H)-ones

2-[3-Methyl-4(4-dialkylaminobenzylidene)-5-oxo-4,5-dihydropyrazol-1-yl] cyclopenta[d]pyrimidin-4(3H)-ones were synthesized by consecutive transformation of 2-hydrazinocyclopenta[d]pyrimidin-4(3H)-one prepared from benzylideneaminoguanidine and ethyl 2-oxocyclopentanoate.

Rational Design and Synthesis of 1-(Arylideneamino)-4-aryl-1H-imidazole-2-amine Derivatives as Antiplatelet Agents

Based on previous studies indicating the pharmacophoric role of a hydrazone group and azole rings for antiplatelet aggregation activity, a few series of compounds with both hydrazone and an azole (imidazole) ring in their structures were synthesized, and their platelet aggregation inhibitory effects were evaluated. Two of these 1-(arylideneamino)-4-aryl-1H-imidazole-2-amine derivatives, compounds 4 a [(E)-1-(benzylideneamino)-4-phenyl-1H-imidazol-2-amine] and 4 p [(E)-4-phenyl-1-((thiophen-2-ylmethylene)amino)-1H-imidazol-2-amine], exhibited IC50 values similar to that of acetylsalicylic acid against collagen as a platelet aggregation inducer. Structural comparison of the synthesized compounds revealed that those with a para-substituted phenyl ring on the imidazole were among the most active compounds against platelet aggregation induced by arachidonic acid (AA), and the presence of a thiophene ring in these compounds maximized their antiplatelet activity.

2-alkylidene-aminoguanidines and methods of use therefor

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging) which contain 2-alkylidene aminoguanidines and derivatives thereof. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Recovery of (1-S)-2-oxo-bornane-10-sulphonate

A process has been developed for the recovery of (1-S)-2-oxo-bornane sulphonic acid (D-camphor-β-sulphonic acid) from contaminated aqueous solutions, particularly from those which arise as mother liquors from the resolution of the racemates of amino compounds wherein said solutions are treated with guanidine bases (or soluble salts thereof) of the formula STR1 in which Ar is an optionally substituted aryl radical at pH about 3.5 to 7.5 and the guanidinium camphorsulphonate is separated off and split. The process is effective even where the mother liquors are contaminated with large amounts of inorganic salts.